NCT03526835: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 560 planned
- Started
- 2 May 2018
- Primary completion
- May 2028
- Arms
- MCLA-158 (Single-Agent), MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI combination chemotherapy, MCLA-158 + FOLFOX combination chemotherapy
- Results
- None posted
- 2 May 2018: Trial started
- 16 May 2018: Trial registered